Servier’s $2.5 B Acquisition of Day One Biopharma: End of Public Listing, New Oncology Pipeline, and Investor Impact
Day One Biopharmaceuticals merges with Servier, closing for $2.5 billion. The deal delists Day One, gives Servier an oncology pipeline, and ends public exposure for shareholders.
- Day One Biopharmaceuticals Inc
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
4 minutes to read
